Cargando…

The costs of developing treatments for Alzheimer's disease: A retrospective exploration

INTRODUCTION: With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development (R&D) investment in Alzheimer's disease (AD), only five novel drugs—all for symptomatic treatment only—have reached FDA approval. Here, we estimate the costs of AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey L., Goldman, Dana P., Simmons‐Stern, Nicholas R., Ponton, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940715/ https://www.ncbi.nlm.nih.gov/pubmed/34581499 http://dx.doi.org/10.1002/alz.12450

Ejemplares similares

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease
por: Rinne, Juha O., et al.
Publicado: (2016)

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
por: Voss, Tiffini, et al.
Publicado: (2018)

Accelerating drug development for Alzheimer's disease through the use of data standards
por: Neville, Jon, et al.
Publicado: (2017)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Alzheimer's disease Archimedes condition-event simulator: Development and validation
por: Kansal, Anuraag R., et al.
Publicado: (2018)

The Heart and Medicine: Exploring the Interconnectedness of Cardiometabolic-related Concerns Through a Systems Biology Approach
por: Lamb, Joseph, et al.
Publicado: (2012)

An amylin analog used as a challenge test for Alzheimer's disease
por: Zhu, Haihao, et al.
Publicado: (2017)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Math and Data Exploration
por: Liu, Dennis
Publicado: (2010)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

Life Sciences Career Exploration
por: Stark, Louisa A.
Publicado: (2011)

Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease
por: Fernandez-Martos, Carmen M., et al.
Publicado: (2016)

Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
por: Calcanes, George, et al.
Publicado: (2019)

Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study
por: Bhattacharjee, Sandipan, et al.
Publicado: (2019)

Financial costs and personal consequences of research misconduct resulting in retracted publications
por: Stern, Andrew M, et al.
Publicado: (2014)

A Golden Age of Brain Exploration
por: Gewin, Virginia
Publicado: (2005)

Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease
por: Huang, Zhiyue, et al.
Publicado: (2017)

Child dental health and the cost-of-living crisis
por: Hancocks, Stephen
Publicado: (2023)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States
por: Prados, Maria J., et al.
Publicado: (2022)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease
por: Taylor, Matthew K., et al.
Publicado: (2017)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease
por: Fischer, Corinne E., et al.
Publicado: (2017)

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)

Analysis of high‐risk pedigrees identifies 11 candidate variants for Alzheimer's disease
por: Teerlink, Craig C., et al.
Publicado: (2021)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease
por: Burfeind, Kevin G., et al.
Publicado: (2017)

Intranasal rifampicin for Alzheimer's disease prevention
por: Umeda, Tomohiro, et al.
Publicado: (2018)

Estrogen activates Alzheimer's disease genes
por: Ratnakumar, Abhirami, et al.
Publicado: (2019)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8v9bh7br9lvvie29knkk1ob4fp